Now that Concert Pharmaceuticals has press released their top line results for CTP-543 8mg twice daily, CTP-543 Results from Interim Analysis of Phase 2a Trial in Patients with Alopecia Areata, a comparison can be made with Pfizer's phase 2 results for drug PFE-06651600 for moderate to severe Alopecia Areata. In the comparison below, I am focusing on SALT % Increase (mean) End of Treatment. In this category CTP-543 had a 42.00% mean increase of SALT score after 24 weeks, versus a 38.13% increase for Pfizer's drug PFE-06651600. Concerts phase 2 study testing up to 8mg, may not be the highest dose available, as the company is currently testing a 12mg arm in the same phase 2 study.
| PFE-06651600 | ||
| Total (n=45) | 24 weeks | |
| Baseline | End of Treatment | |
| SALT (mean) | 88.1 | 54.5 |
| SALT Increase (mean) | -33.6 | |
| SALT % Increase (mean) | 0 | 38.13% |
| % SALT Reduction | % of 45 Patients Achieving Better SALT Scores | |
| 30% | 47.9% | |
| 50% | 37.5% | |
| 75% | 27.0% | |
| 90% | 25.0% | |
| 100% | 12.5% | |
| CTP-543 8mg | ||
| Total (n=38) | 24 weeks | |
| Baseline | End of Treatment | |
| SALT (mean) | 89.1 | 51.7 |
| SALT Increase (mean) | -37.4 | |
| SALT % Increase (mean) | 0 | 42.00% |
| % SALT Reduction | % of 38 Patients Achieving Better SALT Scores | |
| 30% | not measured | |
| 50% | 47.0% | |
| 75% | 29.0% | |
| 90% | 16.0% | |
| 100% | 0.0% |
No comments:
Post a Comment